Caron P, Gaillard J, Barousse C, Bouissou H, Louvet J P, Boulard C
Biomed Pharmacother. 1987;41(3):143-6.
Since Sherwood's report in 1979, contradictory findings have been published with regarding the treatment of primary hyperparathyroidism with Cimetidine. We studied 16 patients with primary hyperparathyroidism treated with 1,200 mg of Cimetidine and followed-up clinically and biochemically. A decrease in serum calcium and urinary CAMP was observed after the fourth week of Cimetidine therapy with no significant change in parathormone levels. In none of the cases did Cimetidine seem to provide a treatment of hyperparathyroidism, a condition which remains curable with surgery.
自1979年舍伍德的报告以来,关于用西咪替丁治疗原发性甲状旁腺功能亢进症,已发表了相互矛盾的研究结果。我们研究了16例接受1200毫克西咪替丁治疗的原发性甲状旁腺功能亢进症患者,并对其进行了临床和生化随访。在西咪替丁治疗第四周后,观察到血清钙和尿环磷酸腺苷(CAMP)下降,而甲状旁腺激素水平无显著变化。在任何病例中,西咪替丁似乎都不能治疗甲状旁腺功能亢进症,而这种疾病通过手术仍然可以治愈。